Korro Bio Inc
KRRO12.570USD
+1.030+8.93%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
118.13M시가총액
손실P/E TTM
자세한 내용은 Korro Bio Inc 회사
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Inc 정보
종목 코드 KRRO
회사 이름Korro Bio Inc
상장일Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
직원 수104
유형Ordinary Share
회계 연도 종료Oct 03
주소One Kendall Square. Building 600-700
도시CAMBRIDGE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02139
전화16174681999
웹사이트https://www.korrobio.com/
종목 코드 KRRO
상장일Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Korro Bio Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
+21482.00%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
+20132.00%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
+21482.00%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
+20132.00%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
수익 분석
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
United States
1.09M
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Tue, Feb 3
마지막 업데이트: Tue, Feb 3
주주
주주 유형
주주
주주
비율
Atlas Venture
12.08%
New Enterprise Associates (NEA)
11.58%
Lynx1 Capital Advisors LLC
7.79%
Driehaus Capital Management, LLC
7.14%
Fidelity Management & Research Company LLC
5.99%
기타
55.43%
주주
주주
비율
Atlas Venture
12.08%
New Enterprise Associates (NEA)
11.58%
Lynx1 Capital Advisors LLC
7.79%
Driehaus Capital Management, LLC
7.14%
Fidelity Management & Research Company LLC
5.99%
기타
55.43%
주주 유형
주주
비율
Investment Advisor
51.04%
Venture Capital
24.12%
Hedge Fund
23.88%
Investment Advisor/Hedge Fund
15.43%
Corporation
5.74%
Research Firm
2.19%
Individual Investor
1.96%
Private Equity
0.34%
Bank and Trust
0.26%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
191
11.02M
117.07%
+1.11M
2025Q3
186
9.33M
99.33%
-1.07M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Atlas Venture
1.14M
12.08%
--
--
Sep 30, 2025
New Enterprise Associates (NEA)
1.09M
11.58%
--
--
Sep 30, 2025
Lynx1 Capital Advisors LLC
733.63K
7.79%
+733.63K
--
Dec 23, 2025
Driehaus Capital Management, LLC
671.98K
7.14%
+91.12K
+15.69%
Sep 30, 2025
Fidelity Management & Research Company LLC
563.68K
5.99%
-75.54K
-11.82%
Sep 30, 2025
Platanus Investment LLC
540.16K
5.74%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
531.97K
5.65%
-8.11K
-1.50%
Sep 30, 2025
The Vanguard Group, Inc.
395.66K
4.2%
+8.92K
+2.31%
Sep 30, 2025
Cormorant Asset Management, LP
465.00K
4.94%
--
--
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
더 보기
iShares Micro-Cap ETF
비율0.05%
Avantis US Small Cap Equity ETF
비율0.02%
Global X Russell 2000 ETF
비율0.01%
Proshares Ultra Russell 2000
비율0.01%
ProShares UltraPro Russell2000
비율0%
SPDR Portfolio MSCI Global Stock Market ETF
비율0%
ProShares Hedge Replication ETF
비율0%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0%
iShares Russell 2000 Growth ETF
비율0%
iShares Russell 3000 ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
날짜
배당락일
유형
비율
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
